Tegmine Therapeutics focuses on developing innovative antibody-based therapies that specifically target glycoproteins, which are prevalent in various solid tumors and contribute to the aggressiveness of cancer. Their proprietary platform, known as TegMiner™, is designed to identify unique cancer epitopes, enabling the creation of new antibodies that significantly enhance therapeutic efficacy while minimizing toxic side effects. This approach aims to address the needs of patients who currently have limited treatment options, thereby advancing the field of cancer therapeutics.

The company's technology leverages advanced methodologies in antibody engineering to produce therapies that are not only effective but also safer for patients. By concentrating on glycoprotein targets, Tegmine Therapeutics is positioned to make substantial contributions to cancer treatment, potentially transforming the landscape for patients suffering from aggressive forms of the disease. Their commitment to innovation in this area underscores their mission to eradicate cancer through cutting-edge scientific advancements.

United States

At Tegmine we target glycoproteins, which are a hallmark of numerous solid cancers and drive aggressive disease. We’ve engineered a system to generate revolutionary new antibody-based therapies for cancer which dramatically increase efficacy while reducing toxic side effects. Our proprietary TegMiner™ platform enables the discovery of unique cancer epitopes and allows us to develop these life-changing new antibodies for patients with unmet needs.

Tegmine Therapeutics

Company Details